Copanlisib - Bayer HealthCare Pharmaceuticals

Drug Profile

Copanlisib - Bayer HealthCare Pharmaceuticals

Alternative Names: Aliqopa; BAY-806946; BAY-841236; Copanlisib hydrochloride

Latest Information Update: 15 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer Schering Pharma
  • Developer All Ireland Cooperative Oncology Research Group; Bayer HealthCare Pharmaceuticals; Chonnam National University Hospital; H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (USA)
  • Class 3-ring heterocyclic compounds; Amides; Antineoplastics; Imidazoles; Morpholines; Pyrimidines; Quinazolines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors; Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Follicular lymphoma; Marginal-zone-B-cell-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Follicular lymphoma
  • Phase III Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma
  • Phase II Cholangiocarcinoma; Diffuse large B cell lymphoma; Endometrial cancer; Mantle-cell lymphoma
  • Phase I/II Breast cancer; Peripheral T-cell lymphoma; Solid tumours
  • Phase I Lymphoma; Urogenital cancer

Most Recent Events

  • 11 Sep 2018 Bayer initiates a phase I trial for healthy volunteers in USA (IV) (NCT03655301)
  • 31 Aug 2018 Bayer plans a phase I trial for healthy volunteers in September 2018 (IV) (NCT03655301)
  • 25 Jul 2018 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in South Korea, Singapore (IV) (NCT03517956)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top